Indoco Remedies Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Indoco Remedies kazanç ve gelirin sırasıyla yıllık 113.9% ve 13.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 112.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 11.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

113.9%

Kazanç büyüme oranı

112.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.7%
Gelir büyüme oranı	13.3%
Gelecekteki özkaynak getirisi	11.2%
Analist kapsamı	Low
Son güncelleme	22 Jan 2025

Gelecekteki son büyüme güncellemeleri

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Jan 24

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Recent updates

Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive

Jan 29

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Jan 24

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

May 24

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Jan 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Sep 16

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

May 21

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Aug 31

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Jul 04

Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price

Mar 09

What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?

Feb 22

Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?

Feb 07

Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 17

Is Indoco Remedies (NSE:INDOCO) A Risky Investment?

Dec 27

Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)

Dec 06

Kazanç ve Gelir Büyüme Tahminleri

NSEI:INDOCO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	22,509	1,437	1,027	N/A	4
3/31/2026	19,712	774	206	N/A	5
3/31/2025	16,593	-465	-982	N/A	4
12/31/2024	17,243	-107	N/A	N/A	N/A
9/30/2024	17,732	321	-3,076	2,220	N/A
6/30/2024	18,223	767	N/A	N/A	N/A
3/31/2024	18,173	985	-2,706	1,567	N/A
12/31/2023	17,958	1,016	N/A	N/A	N/A
9/30/2023	17,356	1,134	-911	1,442	N/A
6/30/2023	16,869	1,281	N/A	N/A	N/A
3/31/2023	16,686	1,423	-284	1,788	N/A
12/31/2022	16,496	1,569	N/A	N/A	N/A
9/30/2022	16,084	1,617	85	1,703	N/A
6/30/2022	15,622	1,537	N/A	N/A	N/A
3/31/2022	15,408	1,548	485	1,738	N/A
12/31/2021	14,368	1,393	N/A	N/A	N/A
9/30/2021	14,110	1,317	257	1,391	N/A
6/30/2021	13,524	1,157	N/A	N/A	N/A
3/31/2021	12,415	930	54	822	N/A
12/31/2020	12,084	734	N/A	N/A	N/A
9/30/2020	11,654	571	387	931	N/A
6/30/2020	11,298	393	N/A	N/A	N/A
3/31/2020	11,066	241	644	1,228	N/A
12/31/2019	10,909	302	N/A	N/A	N/A
9/30/2019	10,640	264	N/A	N/A	N/A
6/30/2019	10,071	111	N/A	N/A	N/A
3/31/2019	9,684	-29	352	1,321	N/A
3/31/2018	10,424	412	N/A	1,227	N/A
3/31/2017	10,968	771	N/A	886	N/A
3/31/2016	10,081	819	N/A	1,122	N/A
3/31/2015	8,570	828	N/A	1,090	N/A
3/31/2014	7,336	580	N/A	988	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: INDOCO önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 6.7% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: INDOCO önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: INDOCO önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: INDOCO şirketinin gelirinin (yıllık 13.3% ) Indian pazarından (yıllık 10.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: INDOCO şirketinin gelirinin (yıllık 13.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: INDOCO 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 11.2 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/30 02:57
Gün Sonu Hisse Fiyatı	2025/01/30 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Indoco Remedies Limited 17 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
Sarabjit Nangra	Angel Broking Private Limited
Srivathsan Ramachandran	Avendus Spark

Indoco Remedies Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 16%

Recent updates

Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive

₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results

Indoco Remedies Limited to Report Q3, 2025 Results on Jan 21, 2025

MD & Executive Director recently bought ₹4.6m worth of stock

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

Consensus EPS estimates fall by 20%

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

Consensus EPS estimates fall by 16%

Full year 2024 earnings: EPS misses analyst expectations

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Consensus EPS estimates fall by 13%

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)